Cue Health raises $100M to boost portable coronavirus test development

Cue has worked with the U.S. Biomedical Advanced Research and Development Authority since 2018, following a $30 million contract to develop a similar test for influenza A and B designed for use at the point-of-care or at home through an online service. (Getty Images)

Portable testing company Cue Health has raised $100 million in new venture capital funding shortly after acquiring a U.S. government contract to develop a rapid, point-of-care coronavirus diagnostic.

The proceeds will be put toward plans to double the company’s footprint in San Diego, home to its manufacturing and business operations, scaling up to over 110,000 square feet. This will support the development and commercialization of a cartridge-based COVID-19 test, currently under emergency authorization review by the FDA.

“The COVID-19 pandemic has highlighted the need for a rapid, easy-to-use platform for diagnostics in decentralized settings to respond to existing and emerging threats,” Cue’s co-founder and CEO, Ayub Khattak, said in a statement.

Webinar

De-risking the Development of Biotherapeutics Using Early Stage In Vitro Expression and Genetic Characterisation Tools

There is a high attrition rate during the development of biotherapeutics impacting the high cost of development. Early identification of the preferred expression host for manufacturing, along with lead candidate screening and material supply can help to reduce both attrition rates and cost.

“Healthcare settings such as nursing homes, emergency departments, and community health clinics need tools to allow them to access molecular test information immediately rather than waiting hours or days for lab results,” Khattak said.

RELATED: J&J partners with San Diego startup Cue to develop portable HIV viral load Dx

The series C round was backed by Decheng Capital, Foresite Capital, Madrone Capital Partners, ACME Capital, Johnson & Johnson Innovation and others. 

In mid-March, Cue was awarded a $13 million contract from the U.S. Biomedical Advanced Research and Development Authority, or BARDA, to develop a portable COVID-19 test that could provide a result in under 25 minutes from a nasal swab.

RELATED: Cue Health reels in $45M in series B financing for its diagnostic products

Cue has worked with BARDA since 2018, following a $30 million contract to develop a similar test for influenza A and B designed for use at the point-of-care or at home through an online service. That test is currently undergoing clinical testing.

“We are excited to welcome strong healthcare and life-science focused investors that align with our vision for how diagnostics should evolve,” Khattak said. “Ultimately, broad distribution of the connected Cue platform to both healthcare professionals and consumers will enable a new model of rapid, on-demand diagnostic testing and enhanced telemedicine capabilities, changing the way important health information is accessed and acted on.”

Suggested Articles

Moderna’s shares shrunk by nearly 5% before the long holiday weekend Thursday after a report out by Stat said the biotech was delaying its trial.

The supermarket chain received an emergency authorization for its own home collection kit for COVID-19 testing, which includes a telehealth consult.

Helsinn Group and MEI Pharma penned a near $500 million biobucks pact for experimental blood cancer drug pracinostat back in 2016.